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Abstract
Background—Inaccurate aortic valve sizing and selection is linked to paravalvular leakage in 
transcatheter aortic valve replacement (TAVR). Here, a novel sizing valvuloplasty conductance 
balloon (SVCB) catheter is shown to be accurate, reproducible, unbiased, and provides real-time 
tool for aortic valve sizing that fits within the standard valvuloplasty procedure.
Methods & Results—The SVCB catheter is a valvuloplasty device that uses real-time electrical 
conductance measurements based on Ohm’s Law to size the balloon opposed against the aortic 
valve at any given inflation pressure. Accuracy and repeatability of the SVCB catheter was 
performed on the bench in phantoms of known dimension and ex vivo in 3 domestic swine aortic 
annuli with comparison to computed tomography (CT) and dilator measurements. Procedural 
workflow and safety was demonstrated in vivo in 3 additional domestic swine. SVCB catheter 
measurements had negligible bias or error for bench accuracy considered as the gold standard 
(Bias: −0.11 ± 0.26 mm; Error: 1.2%), but greater disagreement in ex vivo versus dilators (Bias: 
−0.3 ± 1.1mm; Error: 4.5%), and ex vivo versus CT (Bias: −1.0 ± 1.6 mm; Error: 8.7%). The 
dilator versus CT accuracy showed similar agreement (Bias: −0.9 ± 1.5 mm; Error: 7.3%). 
Repeatability was excellent on the bench (Bias: 0.02 ± 0.12 mm; Error: 0.5%) and ex vivo (Bias: 
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−0.4 ± 0.9 mm; Error: 4.6%). In animal studies, the device fit well within the procedural workflow 
with no adverse events or complications.
Conclusions—Due to the clinical relevance of this accurate, repeatable, unbiased, and real-time 
sizing measurement, the SVCB catheter may provide a useful tool prior to TAVR. These findings 
merit a future human study
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TAVR; annular dimensions; paravalvular leak; CT; Ohm’s Law
INTRODUCTION
Balloon aortic valvuloplasty (BAV) before, or after independent of transcatheter aortic valve 
replacement (TAVR) has become a common procedure for patients with aortic stenosis. 
Anatomical, symptomatic, and functional improvements are sometimes seen with BAV 
independent of TAVR, which are the result of stretching of the valve leftlets and/or annulus 
and the breakage of valvular calcifications and commissural fissures.1 Patient quality of life 
(QOL) is typically improved following BAV, but unchanged long-term mortality and 
restenosis following the procedure have limited its widespread, stand-alone usage.2–4
The emergence of TAVR has led to a resurgence in BAV.5 Prior to TAVR, balloon 
valvuloplasty is used to pre-dilate the native aortic valve and in some cases also to post-
dilate the implanted valve if significant valvular regurgitation or valve misplacement 
occurs.6–7 Initial TAVR outcomes have been favorable with long-term mortality equivalent 
to surgically implanted valve controls.8–9 Nevertheless, numerous multi-center randomized 
trials using both the Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA) and 
CoreValveReValving® system (Medtronic, Minneapolis, MN) have cited even mild degrees 
of paravalvular leakage as an independent predictor related to long-term mortality (i.e., 
leakage in as high as 67% of patients at 1–3 years post-implant).9–13 This paravalvular 
leakage, among other factors, has been shown to be related to inaccurate valve sizing and 
valve size selection.14–16
Aortic valve size is determined prior to or during TAVR procedures using multi-detector 
computed tomography (MDCT), transesophageal echocardiography (TEE), and 
transthoracic echocardiography (TTE).17–22 Since MDCT provides 3-dimensional images to 
visualize eccentricities in valvular area that cannot be seen by 2-dimensional 
echocardiographic slices, measurements made with MDCT can be different than TEE/
TTE.17 A diameter underestimation of 1–1.7mm is reported between echocardiography and 
MDCT/surgical measurements which would have resulted in a different choice for a TAVR 
valve size or resulted in no valve selection (i.e., outside the manufacturer range) in up to 
44% of the cases.18–22 Although, MDCT is seemingly more accurate, it requires an added 
procedure, requires user interpretation of the images, and exposes the patient to high doses 
of x-ray and contrast dye. Therefore, a tool that fits well within the current TAVR workflow 
and provides safe, accurate, and unbiased aortic sizing measurements may be valuable. 
Here, we provide bench, ex vivo, and in vivo validation of a novel aortic sizing 
valvuloplasty conductance balloon (SVCB) catheter that fits well within the clinical TAVR 
Svendsen et al. Page 2
Catheter Cardiovasc Interv. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
workflow to provide real-time, accurate, and unbiased (no image interpretation) dimension 
(cross-sectional area, CSA; or diameter) of the balloon sizing at any inflation pressure or 
volume.
METHODS
The SVCB catheter is a standard valvuloplasty balloon with a 0.035” over-the-wire 
exchange, a set of radiopaque electrodes inside the balloon, a proximal electrode connection, 
and a port for balloon inflation (Figure 1a). The outer electrodes placed inside either end of 
the balloon serve as standard fluoroscopic edge markers in addition to serving as excitation 
sensors for the balloon sizing measurements (Figure 1b – outer electrodes). When connected 
to the computer console via the proximal electrode connector, a small amount of alternating 
electrical current (136 µApp, 1–10kHz) is applied inside the balloon through the outer 2 
electrodes. Based on the conductance measurements made by adjacent pairs of the middle 
electrodes (spaced ~1–2mm apart), the outer CSA and effective balloon diameter can be 
determined and displayed by the console in real-time (i.e., Figure 1b – the sizing 
measurement is made locally at several locations along the balloon length at the various 
adjacent electrode pairs – see Appendix for details on how the sizing measurements are 
calculated based on Ohm’s Law). The SVCB catheters used in this study had a 10 Fr body 
and a ~100 cm length (Figure 1) with a maximum balloon diameter of 25–30 mm.
Bench Validation
Accuracy and repeatability of the SVCB catheter using both compliant (urethane) and non-
compliant (PET) balloons were performed on the bench using circular metal (steel), glass, 
and plastic rigid phantoms that covered all of the balloon (uniform) or a small part of the 
balloon at the measurement location (non-uniform). The phantoms ranged from 20–30mm in 
diameter and were independently measured to determine the true dimension using either a 
set of calipers or through microscopic measurement. The value for the electrical 
conductivity of the injected fluid in the balloon was determined using an independent set of 
phantoms and then randomized repeat measurements were made using a contrast/saline 
mixture inside the balloon (i.e., either an 8:1 or 4:1 saline/contrast mixture using 0.9% NaCl 
solution (Baxter Healthcare; Deerfield, IL) and Omnipaque contrast (350mgI/ml; GE 
Healthcare; Waukesha, WI)). The recorded voltage values along with the other known 
parameters were used to calculate the SVCB catheter sizing measurements (see Eqs. 1–2 in 
the Appendix).
The accuracy of the SVCB catheter measurements was determined by the difference 
between the SVCB catheter and the true phantom measurement (considered as the gold 
standard). Repeatability was determined as the difference between consecutive randomized 
repeat SVCB catheter measurements in the same phantom. The average, standard deviation 
(SD), and root mean square (RMS) error were calculated for the accuracy and repeatability 
measurements. A linear regression (forced through the origin in line with Ohm’s law) and 
Bland-Altman analyses were performed for the accuracy (SVCB catheter vs. true) and 
repeatability (SVCB catheter measurement #1 vs. #2) data as well.23
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In vivo Procedural Workflow
SVCB catheter usage was demonstrated in vivo in 3 normal, domestic swine (57 ± 20 kg). 
Animals were initially sedated using an intra-muscular injection of telazol (2 mg/kg), 
ketamine (1 mg/kg), and xylazine (1 mg/kg) with anesthetic maintenance through intubation 
and ventilation with 100% oxygen and 1–2% isoflurane. The carotid and femoral arteries 
were accessed for the placement of a SVCB catheter across the aortic valve and a diagnostic 
catheter in the ascending aorta. High rate pacing (170–220 bpm) was established prior to 
balloon inflation through right atrial pacing (Medtronic CapSureFix 5568 bipolar lead). 
After placement of the middle electrodes in the center of the valve, inflation of the SVCB 
catheter occurred during high-rate pacing and fluoroscopic monitoring until the indentation 
of the balloon at the aortic annulus was visualized. Inflation of the balloon was made using a 
4:1 to 8:1 saline/contrast mixture. The balloon was then immediately deflated and the high-
rate pacing was stopped. The ECG and other vital signs were monitored during the 
procedure to ensure there was no cardiac arrhythmia risk due to the SVCB conductance 
recordings. All animal procedures followed were in accordance with institutional guidelines 
under an approved IACUC protocol.
Ex vivo Validation
A comparison of the SVCB catheter measurements were completed in explanted normal 
domestic swine hearts (weight = 224±117 gm; n=3). The hearts were taken following 
euthanization under deep anesthesia using an intra-venous injection of potassium chloride. 
All animal protocols were approved by the Institutional Animal Care Use Committee at 
Indiana University-Purdue University Indianapolis.
Size measurement of valve annulus using the SVCB catheter was compared with CT and 
dilator measurements ex-vivo. For the CT validation, the aorta was canulated retrograde and 
the pulmonary veins and proximal coronary arteries were closed off with suture. The hearts 
were pressurized to 100 mmHg with a saline/contrast mixture and placed in a saline bath. 
All scans were completed using a Philips Brilliance 64 CT Scanner and analyzed (Figure 2) 
for cross-sectional area assessment at the level of the aortic annulus by two users (Drs. S. 
Teague and V. Babaliaros). Following the CT scans, the SVCB catheter was placed in the 
aortic annulus and measurements were made using an 8:1 contrast/saline mixture inside the 
balloon (urethane). This procedure was repeated 4 times for each heart and the aortic annular 
size was determined (see Eqs. 1–2 in the Appendix). Following the SVCB balloon 
measurements in all hearts, the apex of the heart was cut and a set of uniform plastic dilators 
(3D Parts Manufacturing LLC; Indianapolis, IN), starting with the smallest, was inserted 
into the aortic annulus until the size of the valve was determined (i.e., the dilator just prior to 
the one in which the dilator could not advance was the recorded size). The differences 
between the SVCB catheter, CT, and dilator measurements were used for comparisons 
between the measurements.
RESULTS
The accuracy of the SVCB catheter measurement compared to the true diameter for phantom 
measurements was −0.11 ± 0.26 mm with a RMS error of 1.2% (Figure 3a–b). For the 
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measurement range from 20–30mm, the phantom relationship between the SVCB measured 
diameter and the true diameter was Dmeasured = 1.0*Dtrue; R2 = 0.99 (Figure 3a; where 
Dmeasured is the SVCB catheter measured diameter and Dtrue is the true diameter). The mean 
difference between repeat bench measurements was 0.02 ± 0.12 mm with a RMS error of 
0.5% (Figure 4a–b). The repeatability relationship on the bench was Dmeasured#2 = 
1.0*Dmeasured#1; R2 = 1 (Figure 4a; where y is SVCB catheter measurement #2 and x is 
SVCB catheter measurement #1).
The temporal change in conductance/diameter was displayed on the computer/console 
screen for the ex vivo and in vivo analyses (Figure 5). The simultaneous and multiple 
diameter measurements along the catheter length in a 20.4mm phantom (Figure 5a) are 
shown during inflation (i.e., increase in the conductance signal) and deflation (i.e., decrease 
in the conductance signal). The real-time measurement of middle electrodes during an in 
vivo measurement (Figure 5b) also shows an increase during inflation and a decrease during 
deflation. The dynamic changes in the balloon dimension are seen during high rate pacing 
oscillations in the in vivo tracing (Figure 5b). The catheter and measurement electrodes are 
clearly seen in vivo under fluoroscopy (Figure 6a) and the balloon is easily visualized during 
inflation (Figure 6b). There were no arrhythmias, adverse events, or complications during 
SVCB usage.
The mean difference between the ex vivo SVCB vs. dilator, SVCB vs. CT, and dilator vs. 
CT measurements for aortic valve measurements was −0.3±1.1 mm, −1.0±1.6 mm, and 
−0.9±1.5 mm with a RMS difference of 4.5%, 8.7%, and 7.3%, respectively. The mean 
aortic valve size for these measurements was 20.9±2.4 mm.
DISCUSSION
The novel SVCB catheter produced highly accurate and repeatable sizing measurements in 
phantoms and ex vivo in swine hearts and demonstrated procedural workflow and safety in 
vivo. A highly significant linear relationship (the slope and R2 both between 0.99–1) was 
observed for the accuracy and repeatability measurements across the full sizing range (20–
30mm) as shown in Figures 3–4. There was excellent agreement in the phantoms and ex 
vivo for accuracy (accuracy: 1.2% bench and 4.5% ex vivo SVCB vs. dilators) and 
repeatability with virtually no bias (phantoms = 0.02 mm; ex vivo = −0.4 mm). Such 
exceptional accuracy and repeatability is rooted in Ohm’s Law (see Appendix Eqs. 1–2) 
where CSA is directly proportional to changes in the measured conductance. Since the 
balloon serves as an insulator, the fundamental principle applies regardless of the 
surrounding environment, as confirmed by the translation of the excellent results from 
metal, plastic, or glass phantoms to the swine hearts. The slightly larger accuracy in the ex 
vivo versus the bench analysis is likely due to the non-simultaneous nature of the SVCB, 
dilator, and CT measurements and due to the fact that the hearts were non-diseased and had 
compliance. Future efforts will be to validate the device in diseased human aortic valves, 
which should have even greater accuracy due to the reduced compliance similar to rigid 
phantoms.
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In addition to sizing accuracy, the SVCB catheter performed seamlessly within the standard 
clinical workflow. The valvuloplasty balloon serves the original intended purpose for 
dilatation, but also provides accurate sizing that can be used prior to implant procedures. 
The results displayed are both the CSA (the direct measurement regardless of geometry) and 
the effective circular diameter based on the CSA measurement. The use of multiple 
electrodes allows for multiple sizing measurements to be made along the catheter length to 
provide a profile of the annulus. Since the balloon will expand slightly larger on either end 
in the left ventricular outflow tract and ascending aorta, the minimum sizing measurement 
along the length provides the annular dimension.
Currently, two valvuloplasty methods have been used to size the aortic valve in conjunction 
with a contrast injection25 or intra-balloon pressure measurement.26 For the contrast 
injection method, a balloon of known diameter is inflated in the aortic valve during a 
contrast injection made in the ascending aorta.25 This method has shortcomings, however, 
for several reasons including: 1) contrast injections are made against the flow of blood in an 
already stenotic valve, 2) visual interpretation of contrast leakage is required around an 
inflated balloon (i.e. high resistance), 3) multiple balloons of various sizes may be needed to 
perform the measurements, and 4) balloon sizes are based on manufacturer ex vivo pressure 
compliance charts which fail to achieve the same dimensions in vivo, thus making balloon 
size assessment sub-optimal.25,27 The intra-balloon pressure based sizing method requires 
the clinician to perform several added steps by inflating the balloon, manually measuring the 
dimension with a caliper, connecting to an indeflator, and deflating the balloon prior to 
usage.26 This method is not ideal because additional inflations and measurements may be 
required to size accurately and an increase in intra-balloon pressure, which can be slight and 
difficult to measure, is used as a correlate for the sizing measurements. The SVCB catheter 
described here addresses the majority of these limitations, since conductance measurements 
are made and displayed in real-time, require no interpretation or contrast injections, and no 
calibration of the device by the clinician during the procedure; and do not depend on a 
pressure surrogate for sizing, but instead utilize a fully validated physical principle (Ohm’s 
Law -Eqs. 1–2) to directly size the valve with unprecedented repeatability and accuracy.
Mis-sizing of the aortic valve prior to TAVR implantation has been an important factor 
linked to paravalvular leakage and mortality, as seen in the PARTNER and CoreValve 
trials.14–16 Although currently the standard imaging modalities for aortic sizing, both MDCT 
and TEE suffer from limitations (additional procedures, image interpretation, >1mm 
difference between the two modalities, high amounts of x-ray exposure (MDCT), and 
measurement inaccuracy (TEE/TTE)). MDCT and TEE do not probe the annulus under the 
distension states which occur with TAVR and thus, MDCT and TEE may under size a 
compliant annulus.17–22 The SVCB catheter adds no additional procedure time (when BAV 
is performed prior to TAVR) and does not require image interpretation or calibration. While, 
MDCT, TEE, and TTE usage will likely continue to be utilized for various TAVR functions, 
like proper valve positioning, the need for these imaging modalities can be supplemented, 
reduced or eliminated with the use of the SVCB.
The electrical signals generated in the SVCB catheter were extremely safe (no major 
arrhythmias, events, or complications) due to the isolated environment created by the 
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balloon and the small, high-frequency nature of the current. Further assurance of the current 
safety has already been proven in catheters and guidewires where there was no balloon to 
provide insulation and the current was injected directly into the coronary and peripheral 
arteries of humans (no safety concerns or adverse events) and animals.28–32 Hence, even if 
the balloon were to rupture, this would pose no electrical risk to the patient. While a saline/
contrast mixture of 4:1 to 8:1 was used in this study, other fluid ratios can be used in the 
future with equally accurate and repeatable results. SVCB catheter was highly versatile 
across various diameters (20–30 mm) and can be extended to smaller and larger diameters if 
necessary for this and various other applications including: pulmonary, tricuspid, or mitral 
valvuloplasty, TAVR post-dilatation, coronary and peripheral post-dilation, stent delivery, 
drug delivery (i.e. drug eluting dilation balloon), cutting balloons, cryoplasty, and/or any 
type of compliant, semi-compliant, or non-compliant balloon for vascular or medical 
applications in which sizing information during inflation is needed.
Limitations
Since the technology measures the balloon size at any inflation pressure, it requires 
apposition of the balloon against the valve leaflets and aortic annulus for sizing of the valve. 
When the balloon is fully opposed to the wall, the sizing measurement provides a CSA 
reading for any valvular size, shape, or disease condition. Since the SVCB catheter 
fundamentally measures CSA and not diameter (although an effective diameter is derived), 
the device can be accurately used to size any shape of aorta, including elliptical. The 
assurance of wall apposition can be gained by using a more compliant SVCB balloon 
catheter that will more easily conform to the shape of the aorta and by observing the 
plateauing of the conductance/CSA reading on the console screen during usage. Future work 
will include information about compliance (change in CSA per change in pressure) and 
radial force (product of pressure and CSA) that provide even further confirmation of full 
balloon expansion to help prevent overexpansion and to determine the propensity for valve 
rupture.
Although accurate valve sizing alone may not completely eliminate paravalvular leakage 
(since other factors like valve positioning can impact this), it may significantly reduce those 
cases in which improper sizing and valve selection play a role in less optimal 
implanation.11,13 Furthermore, the technology is limited in those cases where BAV is not 
recommended or in cases where BAV is not required/typically used. Finally, the body of the 
current catheter is 10Fr in diameter, but the technology is highly adaptable and has already 
been mounted and validated on smaller peripheral24 and coronary balloon catheters (3.7 Fr).
CONCLUSION
A standard valvuloplasty balloon catheter with additional sizing functionality provides an 
accurate, real-time, and unbiased measurement in phantom and ex vivo swine hearts. Future 
bench and in vivo stenosis studies will test the ability of the technology to become a therapy 
delivery tool that may improve the outcome of TAVR and eliminate the need for user-
dependent sizing procedures under TAVR-like conditions.
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APPENDIX
The balloon sizing measurements during inflation and deflation are determined based on a 
physical electrical law (i.e. Ohm’s Law – Eqs. 1 and 2). According to Ohm’s Law, the CSA 
inside the balloon, averaged across any of the adjacent middle electrode pairs, is determined 
by Eq. 1, where I is the known applied current inside the balloon, L is the known, fixed 
distance between adjacent electrodes, V is the measured voltage across the inner electrodes, 
and σ is the conductivity of the fluid inside the balloon. For the SVCB catheter, the contrast/
saline mixture inside the balloon has an inherent σ that can be determined prior to sizing. 
Therefore, since I, L, and σ are known and V is measured in real-time, the balloon size is 
directly related to changes in V and the inner balloon CSA and effective diameter (D) are as 
follows:
Eq. 1
Eq. 2
To obtain the outer balloon dimension (and thus the annular dimension during full inflation), 
twice the wall thickness of the balloon material is added in the calibration and/or 
calculations.
The value for σ is found by relating the measured V inside the SVCB catheter in various 
sized phantoms to the known CSA of the phantoms. The slope of that calibrated I/V versus 
CSA/L relationship in phantoms is the σ for the contrast/saline mixture.28–31
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Figure 1. 
The (a) SVCB catheter showing the balloon at the distal end and the electrode connector, 
inflation port, and over-the-wire exchange on the proximal end. The balloon (b) showing the 
outer electrodes used for the injection of the constant electric current and the middle 
electrodes used for the measurement of the balloon size through voltage measurements.
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Figure 2. 
CT measurement of one of the ex vivo swine hearts.
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Figure 3. 
SVCB catheter bench accuracy in phantoms from 20–30mm. Plot shows the (a) identity 
relationship between the balloon measurement and the true dimension (solid black line as 
the identity line) and the (b) Bland Altman analysis.
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Figure 4. 
SVCB catheter bench repeatability in phantoms from 20–30mm. Figure shows the (a) 
identity relationship between the balloon measurement and the true dimension (solid black 
line as the identity line) and the (b) Bland Altman analysis.
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Figure 5. 
Example of (a) ex vivo and (b) in vivo temporal course of the SVCB catheter diameter 
measurements. The ex vivo analysis (a) when making multiple measurements in a uniform 
20.4mm phantom along the proximal, middle (mid), and distal portions of the catheter and 
the in vivo analysis (b) for a single middle measurement. Note that the oscillations shown in 
(b) are due to the changes in the balloon CSA due to the cardiac cycle during high rate 
pacing. Both the raw and processed data can be displayed in real-time.
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Figure 6. 
SVCB catheter prior to (a) and after full inflation (b) in vivo in swine.
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